Free MDS Forum in TN!
Our partner organization, The MDS Foundation, Inc., is sponsoring another free myelodysplastic syndromes (MDS) Patient & Family/Caregiver Forum in Nashville, Tennessee. When: Thurs., September 19, 2019, 9:00am – 2:30pm Where:…
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay
FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials
According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has approved their investigational new drug…
.jpg)
The Controversy Surrounding Stem Cell Transplants
Genomic studies and advances in technology have increased researchers’ knowledge of several genetic syndromes that put people at risk for acute myeloid leukemia (AML). An article that appeared in…
FREE MDS Forum in Seattle!
Our partner, The MDS Foundation is sponsoring another free MDS Patient & Family/Caregiver Forum. The event will take place in Seattle, Washington on August 10th, 2019. When: Saturday, August 10,…
Tips by a Myelodysplastic Syndromes Patient on How to Navigate the Internet When Researching Your Rare Disease
Jane Biehl Jane Biehl has worked as a professor, rehabilitation counselor, and a librarian. She holds three different degrees, and spreads her knowledge through freelance writing. She also has a…
.jpg)
The New 5F9 Antibody Looks Encouraging as it Targets MDS and AML Leukemia in a Phase 1b Clinical Trial
The California Institute for Regenerative Medicine (CIRM) has funded a study by a company called Forty Seven, Inc. The clinical trial is investigating the benefits of a drug therapy for two cancers…
Researchers Find Gut Bacteria that Can Change Type A Blood to Type O
Blood Donations For many people living with a rare disease such as Beta thalassemia, Hemophilia, Aplastic Anemia, Myelodysplastic syndromes, Acute Promyelocytic leukemia, and others, blood transfusions are not uncommon. For…
source: pixabay.com
Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
According to a story from mdmag.com, a recent study that was presented at the 2019 meeting of the American Society of Clinical Oncology has demonstrated the potential of a two…
Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis
Hereditary Hemochromatosis Hereditary hemochromatosis (HH) is a rare disease caused by hepcidin deficiency or hepcidin insensitivity. Hepcidin naturally regulates iron absorption/distribution in the body. Without hepcidin, HH patients suffer from…
.jpg)
A Look at Progress in Healthcare and a Glimpse into the Future
The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…
Free MDS Foundation Forum in MD!
Patient Worthy's partner the MDS Foundation is hosting a MDS Patient & Family/Caregiver Forum Baltimore, Maryland in conjunction with the University of Maryland Marlene and Stewart Greenebaum Cancer Center. This…
Study Indicates More Research is Needed on Transgender Acute Myeloid Leukemia Patients to Improve Patient Care
In a world that is just beginning to make space for the open discussion of transgender individual's life experiences, there's still a huge gap in the conversation regarding healthcare. This…
Feasibility of Personalized Medicine for Myelodysplastic Syndromes Confirmed by Study
Personalized medicine is the latest craze in patient care. In essence, it refers to the development of treatment options which take into account the patient as an individual. It reduces…
New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!
GT Biopharma has just announced that their Phase 1 clinical trial for Mastocytosis, Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML) has been authorized to begin. Although this investigation had previously…
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay
Phase 3 Myelodysplastic Syndromes Trial Reaches Enrollment Milestone
According to a story from sectorpublishingintelligence.co.uk, the biopharmaceutical company Onconova Therapeutics, Inc. recently announced that they have successfully surpassed the 75 percent milestone for enrollment in the company's Phase 3…
Upcoming FREE MDS Event in PA!
Our partner, The MDS Foundation is sponsoring another free MDS Patient & Family/Caregiver Forum. When: Saturday, April 27, 2019 Where: West Penn Hospital 4800 Friendship Avenue Pittsburgh, PA 15224 Wintergarden Conference Center – First…
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay
Phase 3 Myelodysplastic Syndromes Trial Reaches Enrollment Milestone
According to a story from sectorpublishingintelligence.co.uk, the biopharmaceutical company Onconova Therapeutics, Inc. recently announced that they have successfully surpassed the 75 percent milestone for enrollment in the company's Phase 3…
Updates From Celgene in Follicular Lymphoma, Marginal Zone Lymphoma, Beta Thalassemia, and other Rare Diseases
Celgene Corporation has recently announced two exciting updates for the rare disease community! Update #1 The first big announcement from Celgene was that their supplemental New Drug Application (sNDA) for…
New Phase I/II Trial for Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Multiple Myeloma is Now Underway!
The very first patient in Medigene AG's clinical trial examining MDG1011 has officially received the treatment. This is the company's first human clinical trial for this TCR therapy. The trial…
Patient Advocate Foundation Provides Co-Pay Relief for Rare Disease Patients
What is the Patient Advocate Foundation? The Patient Advocate Foundation (PAF) is a non-profit, formed in 1994 that has one primary aim- eliminate the barriers to treatment too many patients…
Upcoming FREE MDS Forum in AZ!
Our partner, The MDS Foundation is sponsoring another free MDS Patient & Family/Caregiver Forum. This forum will take place in Phoenix, Arizona. When: Saturday, March 9th, 2019 Where: Sheraton Crescent…
Effect of Government Shutdown on Rare Disease Research
The government shutdown hasn't had any startling affects on rare disease research yet, but drug developers have voiced their concern that it could soon begin to hinder the research process.…
A New Phase II Trial for Myelodysplastic Syndromes and Acute Myeloid Leukemia is Underway!
Myelodysplastic syndromes (MDS) is the name used to describe a group of stem cell disorders in which the body can't produce an adequate amount of platelets and blood cells. Currently,…
<a href="https://pixabay.com/users/Pexels/">Pexels</a> / Pixabay
New Model More Effectively Predicts Outcomes in Myelodysplastic Syndromes
According to a story from Science and Technology Research News, a group of researchers from the Cleveland Clinic led by Dr. Aziz Nazha will soon present a new myelodysplastic syndromes…
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay
Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…
